前列腺素衍生物导致眶周综合征的研究进展  

Research progress in prostaglandin-associated periorbital syndrome

作　　者：李汶蔓 林红[1] 李妮[1] Li Wenman;Lin Hong;Li Ni(Department of Ophthalmology,West China Hospital,Sichuan University,Chengdu 610041,China)

机构地区：[1]四川大学华西医院眼科,成都610041

出　　处：《临床眼科杂志》2021年第1期91-94,共4页Journal of Clinical Ophthalmology

摘　　要：前列腺素衍生物降眼压药物是治疗青光眼的一线用药,该类药物降压效果好,应用广泛,全身不良反应较少。目前已经发现的眼部局部不良反应有睫毛生长、虹膜及眶周组织色素沉着增加、眶周脂肪萎缩、上睑沟加深和眼睑变薄等,这些改变被称为前列腺素衍生物导致的眶周综合征(PAPS),围绕PAPS产生了关于前列腺素衍生物治疗非青光眼疾病的基础和临床研究,其中包括治疗甲状腺相关眼病、眼眶疾病、脱发类、脱色素类疾病,本文将从发生机制和临床研究进展方面进行综述,拓展眼科医生的临床思维。Prostaglandin F2αanalogs are the first-line medication for glaucoma,which have good intraocular pressure-lowering effect,wide application and little systematic side-effects.Observed common ocular adverse reactions include eyelash growth,increased pigmentation of the iris and periorbital tissues,periorbital fat atrophy,deepening of the upper eyelid sulcus and thinning of eyelid,etc.These are known as the prostaglandin-associated periorbital syndrome(PAPS).On the basis of PAPS,basic and clinical research on prostaglandin analogs emerged in the treatment of non-glaucoma diseases,including thyroid-associated orbitopathy,orbital disease,alopecia and depigmentation.In this paper,we will review the mechanism and research progress to expand the horizon ophthalmologists.

关 键 词：前列腺素 眶周 甲状腺相关眼病 脱发 脱色素 

分 类 号：R73[医药卫生—肿瘤]